---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-061401"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:44:00.460665+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte enters into Master Services Agreement with Lonza for manufacturing of VAX-24 and VAX-31 components

## Summary
- Agreement effective March 1, 2023, for manufacturing process development and production of polysaccharide antigens, eCRM carrier, and conjugated drug substances.
- Vaxcyte owns IP directly derived from its materials or improvements to its background IP; Lonza owns generally applicable IP and improvements to its background IP.
- Lonza grants Vaxcyte a non-exclusive, worldwide, fully paid-up, transferable license under new general application IP for products manufactured under the agreement.
- Initial term of five years with automatic renewal for two years unless either party gives two years' non-renewal notice before the fifth anniversary.
- Either party may terminate for material breach, insolvency, extended force majeure, or scientific/technical impossibility; Vaxcyte may also terminate on a project-by-project basis.

## SEC filing metadata
- accession: 0001193125-23-061401
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000119312523061401/0001193125-23-061401-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000119312523061401/d476717d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-061401
- JSON: https://secwatch.observer/filing/0001193125-23-061401.json
- Plain text: https://secwatch.observer/filing/0001193125-23-061401.txt

## Key facts
- Material Agreements
  Vaxcyte, Inc. entered into Master Services Agreement for Drug Substances and Microbial Products Development and Manufacturing with Lonza Ltd valued at Vaxcyte will pay Lonza for development and manufacturing services and pass-through expenses incurred (effective 2023-03-01).
  - Action: entry
  - Agreement: supply
  - Counterparty: Lonza Ltd
  - Value: Vaxcyte will pay Lonza for development and manufacturing services and pass-through expenses incurred
  - Effective: 2023-03-01
  source text: On February 28, 2023, Vaxcyte, Inc. (“ Vaxcyte ”) entered into a master services agreement for conjugated polysaccharide drug substances and microbial products development and manufacturing (the “ Master Services Agreement ”) with Lonza Ltd (“ Lonza ”), effective as of March 1, 2023 (the “ Effective Date ”), pursuant to which Lonza will perform manufacturing process development and the manufacture of components for VAX-24 and VAX-31 (formerly VAX-XP), including the polysaccharide antigens, our proprietary eCRM protein carrier and conjugated drug substances.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000119312523061401/0001193125-23-061401-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.